Tsunamic Technologies

Tsunami T-Cell Technologies is a Japanese biotechnology company focused on developing next-generation T-cell therapies using a proprietary large-scale DNA assembly platform. The company's core technology, the TSUNAMI platform, leverages the Bacillus subtilis genome to assemble ultra-large DNA fragments, enabling the creation of complex genetic circuits for cell engineering. This approach allows for the development of multi-functional CAR-T and TCR-T therapies designed to enhance persistence and efficacy against challenging solid tumors. By integrating multiple therapeutic components into a single vector, the company aims to overcome the limitations of current immunotherapy approaches. Tsunami T-Cell Technologies is currently advancing its pipeline through pre-clinical stages while exploring strategic collaborations to expand the application of its synthetic biology platform.